CN109673548B - 尿刊酸在制备抗白斑综合症病毒制剂中的应用 - Google Patents
尿刊酸在制备抗白斑综合症病毒制剂中的应用 Download PDFInfo
- Publication number
- CN109673548B CN109673548B CN201811653341.3A CN201811653341A CN109673548B CN 109673548 B CN109673548 B CN 109673548B CN 201811653341 A CN201811653341 A CN 201811653341A CN 109673548 B CN109673548 B CN 109673548B
- Authority
- CN
- China
- Prior art keywords
- urocanic acid
- white spot
- spot syndrome
- syndrome virus
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 title claims abstract description 56
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 19
- 241000700605 Viruses Species 0.000 title claims description 18
- 241000238557 Decapoda Species 0.000 claims abstract description 45
- 241001124325 Marsupenaeus japonicus Species 0.000 claims abstract description 39
- 241000238030 Procambarus clarkii Species 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 14
- 239000013505 freshwater Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 208000002741 leukoplakia Diseases 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000006052 feed supplement Substances 0.000 claims 1
- 241000696962 White spot syndrome virus Species 0.000 abstract description 65
- 208000015181 infectious disease Diseases 0.000 abstract description 27
- 238000000034 method Methods 0.000 abstract description 16
- 231100000517 death Toxicity 0.000 abstract description 11
- 230000034994 death Effects 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 11
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 239000013535 sea water Substances 0.000 abstract description 6
- 238000009825 accumulation Methods 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000007619 statistical method Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 description 11
- 238000009360 aquaculture Methods 0.000 description 9
- 244000144974 aquaculture Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 6
- 241000238017 Astacoidea Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000091 immunopotentiator Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000229375 Palaemon Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 238000009364 mariculture Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/10—Culture of aquatic animals of fish
- A01K61/13—Prevention or treatment of fish diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/50—Culture of aquatic animals of shellfish
- A01K61/59—Culture of aquatic animals of shellfish of crustaceans, e.g. lobsters or shrimps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Farming Of Fish And Shellfish (AREA)
Abstract
本发明涉及尿刊酸在制备抗白斑综合症病毒制剂中的应用,所述尿刊酸在日本囊对虾及克氏原螯虾受到白斑综合症病毒感染后含量均显著增加;分别对日本囊对虾及克氏原螯虾进行攻毒实验及死亡率统计分析,发现注射尿刊酸能显著抑制白斑综合症病毒在日本囊对虾及克氏原螯虾体内的复制,大幅降低由白斑综合症病毒感染所导致的日本囊对虾及克氏原螯虾的死亡。本发明为白斑综合症病毒的防治提供了一种新的药物,能有效预防白斑综合症病毒的感染及传播,对于已爆发白斑综合症的虾同样适用。而且本发明应用面广,能够同时满足海水虾类及淡水虾类;本发明尿刊酸来自虾体本身,不会破坏海洋及淡水养殖过程中的生态平衡,且在人体内的积累也不会有危害。
Description
技术领域
本发明涉及水产养殖的病毒性疾病防治领域,尤其涉及尿刊酸在制备抗白斑综合症病毒制剂中的应用。
背景技术
对虾是一种重要的海洋经济养殖虾类。国内主要城市人均水产消费量与人均对虾消费量高度相关,2014-2016年,对虾消费需求在170万吨以上并持续稳步增长。对虾养殖是水产养殖业中最具代表性的产业之一。近年来,随着海水养殖规模的不断扩大、集约化程度的不断提高,新发病原和暴发性流行病的发生趋势均显著上升。由各类细菌、病毒感染等引起的各种疾病严重影响了对虾的养殖产业,造成了巨大的经济损失。白斑综合症病毒(white spot syndrome virus,WSSV)是日本囊对虾的主要病原,WSSV对宿主具有泛嗜性,大多数的十足甲壳类海洋生物都会被其感染。克氏原螯虾,俗称小龙虾,是长江中下游地区重要的淡水虾。当前淡水小龙虾国内外市场的消费都呈增长趋势,需求量在不断增长。经多次证实WSSV也是小龙虾养殖产业中虾病爆发的主要病原体。
日本囊对虾及克氏原螯虾作为无脊椎动物,主要依靠先天性免疫系统来抵御病原微生物,这大大增加了养殖过程中的病毒防治工作的难度。养殖池塘中的日本囊对虾及克氏原螯虾一旦暴发白斑综合症,会在短时间内大量死亡,在人工感染实验中感染了WSSV的日本囊对虾及克氏原螯虾死亡率接近100%。长期以来,抗生素在日本囊对虾及克氏原螯虾病害防治中被大量使用,虽然此法可以在一定程度上防治病害,但由于抗生素的长期使用严重威胁了海洋及淡水生态平衡和水产养殖业的可持续发展,现已被严禁使用。目前无脊椎动物免疫与病害防治方面虽然已取得较大进展,但是应对WSSV这种高致死率的病毒感染时,仍缺乏快速有效的防御方法。因而,寻找高效环保的WSSV防治手段对病毒学研究及水产养殖业的可持续发展均具有重要的意义。
目前出现不少抗白斑综合症病毒的药物,如一种防治对虾白斑病的中西复方药物(专利号:200810152729.5),中西复方药物为:黄连、黄芩、黄柏、栀子、黄芪多糖、葡醛内酯、维生素C,混合拌匀成粉末状。使用方法为:将药物与饲料拌在一起,选虾吃食最旺盛的时期每日喂食2次,连用5至7日。一种小龙虾WSSV防治用免疫增强剂(专利号:201611090048.1),免疫增强剂为:维生素E、酵母核酸、左旋咪唑、干扰素、聚乙二醇。其使用方法为:将上述免疫增强剂溶解至水中,搅拌混匀后喷洒至小龙虾养殖水域,3至4小时后,重复喷洒一次。但是虾体从进食药物到消化吸收需要一定的时间,而病毒的复制速度很快,上述发明所需材料种类繁多,且多用于预防,对于已爆发白班综合症的虾作用不大,且见效慢;所包含的材料多为非天然,并非来自于虾本身,是否会对虾造成副作用未知,其残留是否会对人体造成伤害也未知,其对养殖生态平衡的影响也未知。因此,是否适用于现实生产还不得而知。另外目前筛选抗白斑综合症病毒的药物时,仅考虑单一虾种,并没有对其他虾种尤其是不同水质虾种的效果,因此,适用范围单一。
发明内容
针对现有技术中存在的问题,本发明的目的在于提供尿刊酸在制备抗白斑综合症病毒制剂中的应用,本发明的制剂能抑制WSSV在日本囊对虾及克氏原螯虾体内的复制,大幅降低由WSSV感染所导致的日本囊对虾及克氏原螯虾的死亡,减少日本囊对虾及克氏原螯虾养殖产业的损失。
尿刊酸在制备抗白斑综合症病毒制剂中的应用。尿刊酸广泛存在于哺乳动物表皮角质层,在紫外线引起的光免疫抑制过程中发挥着重要的功能。在日本囊对虾和克氏原螯虾的血细胞及淋巴组织中均有尿刊酸的合成,且当日本囊对虾及克氏原螯虾受到WSSV刺激后,尿刊酸的含量急剧增多。
本发明的抗白斑综合症病毒制剂可以只包含尿刊酸单一化学物。
对于筛选尿刊酸作为抗白斑综合症病毒制剂的要求是:
1:应用面广,能够同时满足海水虾类及淡水虾类中WSSV的防治工作。
2:防治结合,筛选及验证过程中都是先感染后治疗,不仅仅局限于预防,对于已爆发白斑综合症的虾同样适用。
3:安全环保,筛选药物来自虾体本身,不会破坏海洋及淡水养殖过程中的生态平衡,且在人体内的积累也不会有危害。
进一步的,所述制剂包括饲料添加剂、固体或者液体药物。
进一步的,所述制剂可用于海水虾类及淡水虾类。
进一步的,所述制剂可用于日本囊对虾和克氏原螯虾。
进一步的,所述尿刊酸能抑制白斑综合症病毒在日本囊对虾及克氏原螯虾体内的复制。将尿刊酸与WSSV共同注射至日本囊对虾及克氏原螯虾体内,不同时间段后检测病毒拷贝数。与对照组相比,尿刊酸处理组病毒的复制显著受到抑制。
进一步的,尿刊酸可大幅降低WSSV感染导致的日本囊对虾及克氏原螯虾的死亡。将尿刊酸与WSSV共同注射至日本囊对虾及克氏原螯虾体内,统计5天的死亡率。与对照组相比,尿刊酸处理组的死亡率大幅降低。
进一步的,所述尿刊酸的添加量为200mM的浓度尿刊酸50μL/虾。
本发明通过研究代谢组在日本囊对虾和克氏原螯虾抵御WSSV感染过程中的功能,发现尿刊酸可能是宿主抗病毒感染过程中的关键物质,体外合成所述尿刊酸并注射至日本囊对虾及克氏原螯虾中能显著WSSV的复制,效率高,可大幅降低由WSSV感染所导致的日本囊对虾及克氏原螯虾的死亡。因此尿刊酸有望成为防治WSSV感染的新药物,广泛应用于水产养殖过程中WSSV的防治。其作为新型药物相较于以往的传统药物,不仅应用面广,能够同时满足海水虾类及淡水虾类中WSSV的防治工作,且尿刊酸在哺乳动物及虾蟹类生物中广泛存在,其作为药物不会破坏海洋及淡水养殖过程中的生态平衡,尿刊酸在体内的积累也不会对人体造成危害,有利于海水及淡水水产养殖业的长期可持续发展。
与现有技术相比,本发明具有以下优势:
(1)本发明的抗白斑综合症病毒制剂可以只包含尿刊酸单一化学物,目前多为多种物质的混合物,本发明更易应用于实际生产。
(2)本发明应用面广,能够同时满足海水虾类及淡水虾类中WSSV的防治,抗WSSV效率高且安全环保,可能成为一种新型的防治WSSV感染的药物。
(3)本发明尿刊酸的筛选及验证过程中都是先感染后治疗,不仅仅局限于预防,对于已爆发白斑综合症的虾同样适用,而现有技术多为提高虾的免疫力,预防WSSV的侵染。
(4)本发明尿刊酸来自虾体本身,不会破坏海洋及淡水养殖过程中的生态平衡,且在人体内的积累也不会有危害。
(5)本发明尿刊酸可显著抑制WSSV在日本囊对虾及克氏原螯虾体内的复制,大幅降低由WSSV感染所导致的日本囊对虾及克氏原螯虾的死亡。
附图说明
图1为利用WSSV及PBS缓冲液处理日本囊对虾及克氏原螯虾后,血细胞及淋巴组织中尿刊酸的GC-MC检测结果图;
图2为尿刊酸及PBS对照组对日本囊对虾体内WSSV复制的影响;将尿刊酸或PBS溶液混合WSSV后注射至日本囊对虾体内,检测WSSV感染0、24、48和72小时后WSSV的拷贝数;
图3为尿刊酸及PBS对照组对克氏原螯虾体内WSSV复制的影响;将尿刊酸或PBS溶液混合WSSV后注射至克氏原螯虾体内,检测WSSV感染0、24、48和72小时后WSSV的拷贝数;
图4为尿刊酸及PBS对照组对WSSV致死日本囊对虾的影响;将尿刊酸或PBS溶液混合WSSV后注射至日本囊对虾体内,统计WSSV感染5天内日本囊对虾的死亡率;
图5为尿刊酸及PBS对照组对WSSV致死克氏原螯虾的影响;将尿刊酸或PBS溶液混合WSSV后注射至克氏原螯虾体内,统计WSSV感染5天内克氏原螯虾的死亡率。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将结合附图对本发明作进一步地详细描述。
实施例1:
筛选日本囊对虾及克氏原螯虾体内抗WSSV感染关键物质的试验
将体重10g左右的日本囊对虾及20g左右的克氏原螯虾在室内水温25℃、每天换水1/5条件下暂养3天后,用1ml注射器于虾第2-3腹节肌肉注射50μL/只PBS缓冲液或WSSV感染液。分别在注射后的0h、4h、6h、24h取虾血细胞及淋巴组织,用于GC-MC检测。
结果见图1。结果表明尿刊酸在日本囊对虾及克氏原螯虾受到WSSV感染后含量显著增加,尤其是6h和24h,其含量相较于PBS对照组急剧增多。
实施例2:
尿刊酸抑制WSSV在日本囊对虾及克氏原螯虾体内增殖的试验
给日本囊对虾及克氏原螯虾注射50μL/只WSSV感染液,24h后再注射50μL/只尿刊酸溶液(200mM)或PBS溶液,WSSV感染0h、24h、48h、72h后,将虾背部肌肉剪取适量,用组织基因组DNA提取试剂盒(Tiangen)抽提总DNA,然后再用TAKARA的Premix Ex TaqTM(ProbeqPCR)的试剂盒检测目的基因的特异片段,检测条件为95℃预变性4min;95℃5s,52℃30s,72℃20s,循环45次。用于荧光定量PCR的引物分别为P1,P2。
P1:5’-ATGTCTGCATCTTTAAT-3’;P2:5’-TTATGACACAAACCTAT-3’。
结果见图2及图3,尿刊酸注射后48h和72h,日本囊对虾及克氏原螯虾体内WSSV的拷贝数显著低于PBS及空白对照组,表明尿刊酸可以显著抑制WSSV在日本囊对虾及克氏原螯虾体内的增殖。
实施例3:
尿刊酸降低WSSV感染后日本囊对虾及克氏原螯虾累积死亡率的试验
按实施例2的方法实施WSSV感染及尿刊酸(或PBS)注射实验。WSSV感染后每天观察3次,及时捡出死亡和濒死虾,记录死亡数并持续观察5天。
结果见图4及图5,不同处理组日本囊对虾及克氏原螯虾的死亡率随时间而升高,PBS注射组及未处理组的死亡率相近,而WSSV+尿刊酸注射组的死亡率显著性地低于WSSValone注射组。表明WSSV感染日本囊对虾及克氏原螯虾后,注射尿刊酸可大幅降低由WSSV感染所导致的虾死亡。
Claims (5)
1.尿刊酸在制备抗白斑综合症病毒制剂中的应用。
2.根据权利要求1所述尿刊酸在制备抗白斑综合症病毒制剂中的应用,其特征在于,所述制剂包括饲料添加剂、固体或者液体药物。
3.根据权利要求1所述尿刊酸在制备抗白斑综合症病毒制剂中的应用,其特征在于,所述制剂用于海水虾类及淡水虾类。
4.根据权利要求1所述尿刊酸在制备抗白斑综合症病毒制剂中的应用,其特征在于,所述制剂用于日本囊对虾和克氏原螯虾。
5.根据权利要求4所述尿刊酸在制备抗白斑综合症病毒制剂中的应用,其特征在于,所述尿刊酸的添加量为200mM的浓度尿刊酸 50μL/虾。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811653341.3A CN109673548B (zh) | 2018-12-29 | 2018-12-29 | 尿刊酸在制备抗白斑综合症病毒制剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811653341.3A CN109673548B (zh) | 2018-12-29 | 2018-12-29 | 尿刊酸在制备抗白斑综合症病毒制剂中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109673548A CN109673548A (zh) | 2019-04-26 |
CN109673548B true CN109673548B (zh) | 2021-08-06 |
Family
ID=66191749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811653341.3A Active CN109673548B (zh) | 2018-12-29 | 2018-12-29 | 尿刊酸在制备抗白斑综合症病毒制剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109673548B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1318564A (zh) * | 2000-04-19 | 2001-10-24 | 中国科学院水生生物研究所 | 识别对虾白斑杆状病毒单链抗体的制备方法 |
CN101679293A (zh) * | 2007-06-11 | 2010-03-24 | 瓦莱塔健康私人有限公司 | 具有治疗免疫相关性和炎症性疾病作用的尿刊酸衍生物 |
CN102716148A (zh) * | 2012-06-18 | 2012-10-10 | 淮阴师范学院 | 咪唑丙烯酸铜、锌配合物/凹土基抗菌剂的制备方法及其应用 |
CN106616030A (zh) * | 2016-12-08 | 2017-05-10 | 安徽省农业科学院水产研究所 | 一种用于防治克氏原螯虾白斑综合症的复方中草药制剂及其方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001079469A2 (en) * | 2000-04-14 | 2001-10-25 | University Of South Carolina Research Foundation | Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
-
2018
- 2018-12-29 CN CN201811653341.3A patent/CN109673548B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1318564A (zh) * | 2000-04-19 | 2001-10-24 | 中国科学院水生生物研究所 | 识别对虾白斑杆状病毒单链抗体的制备方法 |
CN101679293A (zh) * | 2007-06-11 | 2010-03-24 | 瓦莱塔健康私人有限公司 | 具有治疗免疫相关性和炎症性疾病作用的尿刊酸衍生物 |
CN102716148A (zh) * | 2012-06-18 | 2012-10-10 | 淮阴师范学院 | 咪唑丙烯酸铜、锌配合物/凹土基抗菌剂的制备方法及其应用 |
CN106616030A (zh) * | 2016-12-08 | 2017-05-10 | 安徽省农业科学院水产研究所 | 一种用于防治克氏原螯虾白斑综合症的复方中草药制剂及其方法 |
Non-Patent Citations (2)
Title |
---|
Meta-analysis of antiviral protection of white spot syndrome virus vaccine to the shrimp;Shu-Ying Feng 等;《Fish and Shellfish Immunology》;20180717(第81期);第260-265页 * |
尿刊酸的免疫抑制作用研究进展;夏济平 等;《国外医学皮肤性病学分册》;19980831;第24卷(第4期);第213-215页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109673548A (zh) | 2019-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Deng et al. | Effects of a yeast‐based additive on growth and immune responses of white shrimp, Litopenaeus vannamei (B oone, 1931), and aquaculture environment | |
Tanekhy et al. | Expression of innate immunity genes in kuruma shrimp Marsupenaeus japonicus after in vivo stimulation with garlic extract (allicin). | |
Wu et al. | Effect of Coriolus versicolor polysaccharides on the hematological and biochemical parameters and protection against Aeromonas hydrophila in allogynogenetic crucian carp (Carassius auratus gibelio) | |
Zhang et al. | Effect of dietary complex Chinese herbal medicine on growth performance, digestive enzyme activities in tissues and expression of genes involved in the digestive enzymes and antioxidant enzymes and bacterial challenge in Litopenaeus vannamei | |
CN109609504B (zh) | 一种miR-276模拟物在制备广谱抗白斑综合症病毒药物中的应用 | |
CN112375708B (zh) | 一种抗白斑综合征病毒和十足目虹彩病毒1的制剂及其制备方法 | |
CN104888187A (zh) | 一种防治异育银鲫鳃出血疾病的药物组合物及其制备方法 | |
CN109673548B (zh) | 尿刊酸在制备抗白斑综合症病毒制剂中的应用 | |
Sunish et al. | Actinomycetes as a promising candidate bacterial group for the health management of aquaculture systems: A review | |
CN110013485B (zh) | 反义核酸AMO-miR-9875在制备抗白斑综合症病毒制剂中的应用 | |
Isnani et al. | Dietary supplementation with Phyllanthus urinaria and Terminalia catappa enhances innate immunity and resistance to white spot syndrome virus in whiteleg shrimp (Penaeus vannamei) | |
CN109913453B (zh) | 一种AMO-miR-137在制备广谱抗白斑综合症病毒制剂中的应用 | |
CN105724826B (zh) | 一种对虾饲料添加剂及其应用 | |
CN104664068A (zh) | 一种水禽专用复合维生素免疫多糖微乳液制剂及其制备方法和应用 | |
CN1290429C (zh) | 预防和治疗鱼类和有壳水生动物感染性疾病的药物 | |
Pan et al. | Immunomodulatory and growth promoting effects of peptidoglycan supplementation in black tiger shrimp Penaeus monodon Fabricius 1798 | |
CN110042100B (zh) | 一种反义核酸AMO-miR-307在制备抗白斑综合症病毒制剂中的应用 | |
CN109943562B (zh) | 一种miR-2反义核酸在制备广谱抗白斑综合症病毒制剂中的应用 | |
AU2021102943A4 (en) | Chinese Herbal Medicine Bait for Improving Disease Resistance Immunity of Grass Carp | |
Yan et al. | The enhancement effect of low-dose dietary lipopolysaccharide on the growth and immunity of Litopenaeus vannamei, and transcriptome analysis | |
Yuvaraj et al. | Immunomodulatory effects of seagrass Halophila ovalis polysaccharide mixed feed in adult black tiger shrimp Penaeus monodon and its protective efficacy against white spot syndrome virus infection | |
CN109852616B (zh) | 一种wsv049的siRNA在制备白斑综合症病毒制剂的应用 | |
El-Desouky et al. | Effect of Zingiber officinalis and Cyanodon dactylon against pH stress in giant freshwater prawn Macrobrachium rosenbergii. | |
Pothiraj et al. | Disease Management and Prophylaxis by Immunostimulants | |
Li et al. | Effects of Alpinia officinarum stems and leaves extract on growth performance, non-specific immunity, and intestinal microflora of Litopenaeus vannamei |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |